Prostate Cell News 9.35 September 14, 2018 | |
| |
TOP STORYSince prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer (PCa) cells in > 90% of PCa patient population, a PSMA-targeted near-infrared agent (OTL78) was designed and synthesized. OTL78 bound to PSMA-expressing cells with high affinity, concentrated selectively to PSMA-positive cancer tissues, and cleared rapidly from healthy tissues with a half-time of 17 min. [Clin Cancer Res] Abstract | Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators revealed the transcriptional profile of epithelial-mesenchymal plasticity and highlighted the unique transcriptional properties of mesenchymal-to-epithelial reverting transition. [Oncogene] Full Article Researchers demonstrated that the TMPRSS2:ERG fusion protein increased the expression of osteoblastic markers, including collagen type I alpha 1 chain and alkaline phosphatase, as well as endothelin-1, a protein with a documented role in osteoblastic bone lesion formation. [Cancer Lett] Abstract Endothelial Cells Promote Metastasis of Prostate Cancer by Enhancing Autophagy Scientists demonstrated that endothelial cells secreted large amount of CCL5 and induced autophagy by suppressing androgen receptor expression in prostate cancer cell lines. Elevated autophagy accelerated focal adhesions protein disassembly and promoted prostate cancer invasion. [J Exp Clin Cancer Res] Full Article P53 Enhances Apoptosis Induced by Doxorubicin Only under Conditions of Severe DNA Damage Overexpression of p53 only enhanced apoptosis under conditions of severe DNA damage induced by high concentrations of doxorubicin in LNCaP cells. The combination of doxorubicin with CFS-1686 generated DNA damage and replication stress simultaneously, resulting in a synergistic apoptotic effect in prostate cancer cells. [Cell Cycle] Abstract The expression of androgen receptor downregulated the expression of both cluster of differentiation 44 (CD44) and sex-determining region Y (SRY)-box 2 (SOX2) in PC3 cells. SOX2 knockdown attenuated not only the expression of SNAIL and SLUG but also the migration and tumorsphere formation in PC3 cells. [J Cell Biochem] Full Article The authors prepared a multifunctional antioxidant nanoliposome containing PTEN plasmid and cerium oxide nanoparticles. The efficient delivery of PTEN plasmid to human prostate cancer cells led to restoration of the expression of lost PTEN protein in the cell cytoplasm. [J Biomed Mater Res A] Abstract miR-301a Expression: Diagnostic and Prognostic Marker for Prostate Cancer Investigators demonstrated that miR-301a inhibited the pro-apoptotic function of RUNX3, and activated ROCK1-mediated pro-survival signal in prostate cancer. Silencing miR-301a initiated the pro-apoptotic function of RUNX3 by inhibiting ROCK1 expression in prostate cancer cells. [Urol Oncol] Abstract A Short Peptide Reverses the Aggressive Phenotype of Prostate Cancer Cells Researchers investigated the effects of a short peptide derived from the gN helix domain of FGF8b on the metastatic behaviors of prostate cancer cells. They demonstrated that the synthetic peptide might reverse the effects of FGF8b on cell proliferation, migration and invasion by suppressing the activation of MAPK and Akt signaling cascades, and reducing the expression of the metastasis-related proteins, resulting in the improvement of the aggressive phenotype of the prostate cancer cells. [Eur J Pharmacol] Abstract GADD45β-silenced LNCaP cells showed suppressed testosterone-induced 5α-reductase 2 and androgen receptor expression compared to control LNCaP cells. After 21-days of testosterone treatment, prostate weight and stromal tissue increment were relatively lower in GADD45β−/− than wild-type counterpart mice. [Life Sci] Abstract Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSThe authors summarize the role of Wnt signaling inhibitors in the pathogenesis of prostate cancer for a better understanding and hence a better management of this disease. [J Cell Physiol] Abstract Osteoblastic Factors in Prostate Cancer Bone Metastasis A better understanding of how prostate cancer induces aberrant bone formation and how the aberrant bone affects the progression and treatment of the disease may improve the therapies for this disease. [Curr Osteoporos Rep] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSThe Centre for Probe Development and Commercialization (CPDC) and the McMaster Nuclear Reactor facility announced that they have signed an agreement to explore the development of processes to produce rare and high-value medical radioisotopes utilizing the nuclear reactor at McMaster University in Hamilton. [Centre for Probe Development and Commercialization] Press Release Luye Pharma announced that its independently developed drug, Goserelin Acetate Extended-release Microspheres for Injection (LY01005), has entered Phase III clinical trials for prostate cancer in China. Meanwhile, LY01005 is currently under Phase I clinical trials in the U.S. via part 505(b) (2) of the United States Federal Food, Drug and Cosmetic Act. [Luye Pharma Group] Press Release U.S. Department of Defense Funds UIC Research on Prostate Cancer A new three-year grant totaling nearly $1 million from the U.S. Department of Defense will fund University of Illinois at Chicago (UIC) research on the gene SELENOF and its role in the development of prostate cancer among black men. [The Board of Trustees of the University of Illinois] Press Release Boston Scientific Announces Agreement to Acquire Augmenix, Inc. Boston Scientific announced that it has entered into a definitive agreement to acquire Augmenix, Inc.. The transaction consists of an upfront cash payment of $500 million, and up to $100 million for reaching sales-based milestones. [Boston Scientific Corporation] Press Release | |
| |
POLICY NEWSEurope’s Academics Fail to Report Results for 90% of Clinical Trials European academics are failing abysmally when it comes to reporting the results of clinical trials, a study has revealed. An analysis of data from the European Union’s Clinical Trial Register — published in The BMJ — shows that around 50% of the listed trials have not complied with guidelines that say results must be reported within 12 months. [Nature News] Editorial Prominent Health Policy Researcher Resigns from Dartmouth Over Plagiarism Dispute Dr. H. Gilbert Welch, one of the country’s top health care policy scholars, has resigned from his faculty position at Dartmouth College, after an investigation by the school concluded that he had committed research misconduct. [STAT News] Editorial Advocate for Women in Science Wins Prestigious Lasker Award Pioneers in anaesthesiology, DNA structure and RNA biology are this year’s Lasker Awards recipients. The annual prize rewards achievements in biomedical research and is often considered a precursor to the Nobel. [Nature News] Editorial Peer Reviewers in Developing Nations Are Underrepresented, Report Suggests Combined, scientists spend nearly 70 million hours peer reviewing manuscripts for scholarly journals every year, a new report says. But too much of the onus rests on researchers in wealthy countries, according to the report by the company Publons—based in London and Wellington—which enables researchers to track and claim credit for the peer reviews they perform. [ScienceInsider] Editorial
| |
EVENTSNEW 107th Annual Meeting of the Japanese Urological Association (JUA2019) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Genitourinary Cancers (Columbia University Medical Center) Postdoctoral Fellowship – Prostate Cancer Progression (Aarhus University) Postdoctoral Position – Translational Cancer Research (University of California, Davis) Postdoctoral Fellow/Research Scientist – Prostate Cancer (Università della Svizzera italiana) Research Fellow – Personalized Medicine of Anti-Cancer Therapy (Mayo Clinic) Senior Research Scientist – Prostate Cancer Research (University of California, San Francisco) Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities) Research Fellow – Prostate Cancer (Sechenov University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|